Segunda línea de tratamiento de pacientes con NSCLC PD-L1 positivo: - page 5

Immune checkpoint inhibitors in
lung cancer: antiPD-1/PD-L1
Target Antibody Development stage
Phase 1 Phase 2 Phase 3
PD-1
Nivolumab
(BMS-936558)
Pembrolizumab
(MK-3475)
PD-L1
Durvalumab
(MEDI-4736)
Atezolizumab
(MPDL3280A)
Avelumab
(MSB0010718C)
CTLA-4
Ipilimumab
Tremelimumab
(+durvalumab)b
NSCLC SCLC Data reported
5
PD-1
PD-1
B7.1
X
PD-L1 PD-L2
Tumour
cell
PD-L1 T cell
X
B7.1
Macrophage
PD-1
PD-1
B7.1
X
PD-L1 PD-L2
Tumour
cell
PD-L1 T cell
X
B7.1
Macrophage